Bank of America
MGX icon

Bank of America’s Metagenomi Therapeutics MGX Stock Holding History

Bank of America’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-42
Closed -$68 – 6972
2025
Q4 		$68 Sell
42
-18,724
-100% -$40.5K ﹤0.01% 6901
2025
Q3 		$44.5K Buy
18,766
+15,682
+508% +$31.8K ﹤0.01% 6869
2025
Q2 		$4.56K Sell
3,084
-25,746
-89% -$40.3K ﹤0.01% 7312
2025
Q1 		$39.2K Buy
28,830
+7,717
+37% +$18.4K ﹤0.01% 6811
2024
Q4 		$76.2K Buy
21,113
+17,491
+483% +$42.2K ﹤0.01% 6517
2024
Q3 		$7.86K Buy
3,622
+327
+10% +$1.13K ﹤0.01% 6931
2024
Q2 		$13.4K Buy
3,295
+146
+5% +$1K ﹤0.01% 6833
2024
Q1 		$33.2K Buy
+3,149
New +$36.2K ﹤0.01% 6634

Other funds holding MGX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of America's MGX Position: Q1 2026 in Review

Bank of America sold out of Metagenomi Therapeutics (MGX) in Q1 2026, closing a stake of 42 shares — an estimated $68 sold.

Bank of America first reported a position in MGX in Q1 2024 and held it in 8 quarters. The position peaked at $76.2K in Q4 2024. 48 funds tracked by Wall St. Rank hold MGX as of Q1 2026.

  • Bank of America reported no remaining Metagenomi Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 42 Metagenomi Therapeutics shares in Q1 2026, an estimated $68.
  • Bank of America first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 8 quarters.
  • Bank of America's Metagenomi Therapeutics position peaked at $76.2K in Q4 2024.
  • 48 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.